Loading…
PTC Therapeutics, Inc. is projected to rise to $88.63 by 2027, a +25% move from its current price of $70.66. PTCT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $68.99 | $70.68 | $72.42 | +0.03% |
| May 30 | $68.32 | $70.70 | $73.17 | +0.06% |
| May 31 | $67.82 | $70.73 | $73.76 | +0.09% |
| Jun 1 | $67.40 | $70.75 | $74.26 | +0.13% |
| Jun 2 | $67.04 | $70.77 | $74.71 | +0.16% |
| Jun 3 | $66.71 | $70.79 | $75.13 | +0.19% |
| Jun 4 | $66.41 | $70.82 | $75.51 | +0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $66.41 | $70.82 | $75.51 | +0.22% |
| Week 2 | $64.82 | $70.97 | $77.71 | +0.44% |
| Week 3 | $63.65 | $71.13 | $79.49 | +0.66% |
| Week 4 | $62.70 | $71.28 | $81.04 | +0.88% |
| Week 5 | $61.89 | $71.44 | $82.46 | +1.10% |
| Week 6 | $61.19 | $71.60 | $83.78 | +1.33% |
| Week 7 | $60.55 | $71.75 | $85.03 | +1.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company markets multiple therapies across serious rare disease areas, including Translarna and Emflaza for Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Its development pipeline includes Sepiapterin for phenylketonuria, the PTC518 splicing platform for Huntington's disease, and inflammation and ferroptosis platforms including vatiquinone for Friedreich's ataxia. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
The company distributes its products through third-party distributors and collaborates with multiple partners. Its work spans United States and international markets, positioning it within the Healthcare sector as a therapeutics-focused organization dedicated to rare disorders.
PTC Therapeutics carries a formal stock listing in the Healthcare space and operates with roots dating back to its incorporation in 1998, with headquarters in Warren, New Jersey.
PTC Therapeutics, Inc. (PTCT) is categorized in Healthcare and is currently trading with a price of $68.81 and a market capitalization of $5.71B. The stock is ranked 1248 by market cap among listed equities.
The current price sits near its short- and longer-term technical averages, suggesting a measured baseline in the market. The stock’s market position reflects a mid-to-large cap profile within the healthcare space.
From a price-outlook perspective, the forecast indicates a bullish trajectory over the multi-year horizon, with substantial upside potential projected through 2050 under the provided scenario.
A major floor 17.5% below — a decisive break under it would weaken the trend.
The nearest floor, 8.7% below — buyers have tended to step in here.
The nearest ceiling, 8.8% above — a clean break opens room to run.
A major ceiling 17.5% above — clearing it would confirm fresh momentum.
Key PTCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PTCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $69.59 | Buy | $69.72 | Buy |
| MA 10 | $70.60 | Buy | $70.04 | Buy |
| MA 20 | $69.40 | Buy | $69.98 | Buy |
| MA 50 | $69.13 | Buy | $69.69 | Buy |
| MA 100 | $70.45 | Buy | $69.51 | Buy |
| MA 200 | $68.33 | Buy | $66.53 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.96 | Neutral |
| Stoch RSI (14) | 46.42 | Neutral |
| CCI (20) | 26.49 | Neutral |
| Williams %R (14) | -50.08 | Info |
| MACD (12,26,9) | -0.23 | Sell |
| ROC (12) | -4.11 | Sell |
| Bollinger %B (20,2) | 0.59 | Neutral |
| Stochastic %K (14) | 49.92 | Neutral |
| TRIX (15) | 0.10 | Buy |
| Awesome (5,34) | -0.38 | Sell |
| Ultimate (7,14,28) | 49.19 | Neutral |
| Momentum (10) | -4.36 | Sell |
| Aroon Osc (25) | 8.00 | Buy |
| Hull MA (9) | 68.48 | Buy |
| ADX (14) | 11.22 | Neutral |
| ATR (14) | 1.59 | Info |
The 30-day technical picture shows a bullish tilt in sentiment with a relatively balanced near-term momentum. The RSI(14) is 50, placing it in a neutral footing on momentum indicators while price action hovers around key moving averages.
The 50-day simple moving average (SMA) is $68.99, and the 200-day simple moving average (SMA) is $68.12, suggesting the price is near a consolidation zone around its longer-term trend. Support sits at $64.49 and resistance at $76.85, providing defined levels for near-term trading rails.
The 30-day price range spans from $58.83 to $80.48, indicating a broad, volatile but contained activity band over the past month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $62.82 | $70.66 | $97.18 | 0% | Neutral | |
| $71.05 | $88.63 | $116.64 | +25% | Bullish | |
| $72.24 | $92.28 | $125.43 | +31% | Bullish | |
| $79.31 | $103.34 | $144.09 | +46% | Bullish | |
| $81.01 | $107.43 | $153.08 | +52% | Bullish | |
| $88.31 | $119.00 | $172.83 | +68% | Bullish | |
| $108.41 | $148.27 | $219.06 | +110% | Bullish | |
| $117.64 | $163.17 | $244.85 | +131% | Bullish | |
| $126.63 | $177.98 | $270.94 | +152% | Bullish | |
| $136.54 | $194.36 | $299.87 | +175% | Bullish | |
| $199.17 | $300.22 | $490.01 | +325% | Bullish | |
| $323.18 | $536.98 | $952.01 | +660% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $62.82 | $70.66 | $83.36 | +0.00% |
| June 2026 | $62.22 | $72.90 | $87.30 | +3.16% |
| July 2026 | $61.60 | $72.71 | $88.13 | -0.25% |
| August 2026 | $62.53 | $74.23 | $90.81 | +2.09% |
| September 2026 | $63.79 | $76.10 | $93.80 | +2.52% |
| October 2026 | $62.93 | $75.41 | $93.58 | -0.91% |
| November 2026 | $62.37 | $75.02 | $93.65 | -0.52% |
| December 2026 | $64.11 | $77.41 | $97.18 | +3.18% |
Click any year to see its month-by-month PTCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PTCT to range from $62.82 to $97.18 through 2026. The $70.66 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The PTCT price prediction for 2027 points to an average of $88.63 (low $71.05, high $116.64) — a potential gain of +25% on today's $70.66. Buyers look set to stay in control over this stretch.
In 2028, PTCT is projected to trade between $72.24 and $125.43, averaging $92.28 — a potential gain of +31% from today's $70.66. That is up +4% on the projected 2027 average. Momentum favours further upside here.
PTC Therapeutics, Inc.'s 2029 outlook centres on $103.34, within a $79.31 to $144.09 range. That is up +12% on the projected 2028 average. That marks a +46% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, PTCT could reach as high as $153.08, with a base case around $107.43 and support toward $81.01 — roughly +52% from $70.66. Momentum favours further upside here.
Expect PTCT to range from $88.31 to $172.83 through 2031. The $119.00 average target implies a +68% move from current prices. That is up +11% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The PTCT price prediction for 2032 points to an average of $148.27 (low $108.41, high $219.06) — a potential gain of +110% on today's $70.66. Momentum favours further upside here.
In 2033, PTCT is projected to trade between $117.64 and $244.85, averaging $163.17 — a potential gain of +131% from today's $70.66. That is up +10% on the projected 2032 average. Buyers look set to stay in control over this stretch.
PTC Therapeutics, Inc.'s 2034 outlook centres on $177.98, within a $126.63 to $270.94 range. That is up +9% on the projected 2033 average. That marks a +152% change versus current levels. Momentum favours further upside here.
By 2035, PTCT could reach as high as $299.87, with a base case around $194.36 and support toward $136.54 — roughly +175% from $70.66. Buyers look set to stay in control over this stretch.
Expect PTCT to range from $199.17 to $490.01 through 2040. The $300.22 average target implies a +325% move from current prices. That is up +54% on the projected 2035 average. Momentum favours further upside here.
The PTCT price prediction for 2050 points to an average of $536.98 (low $323.18, high $952.01) — a potential gain of +660% on today's $70.66. Buyers look set to stay in control over this stretch.
Investing $1,000 in PTCT today (≈ 14.152279 PTCT) could be worth
$7,599.46
+$6,599.46 (+660%) by 2050 · US Dollar
Based on the average projected PTCT price of $536.98 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PTCTwould be worth at today's price.
$1,000 invested in PTCT on May 27, 2025 (≈ 20.894275 PTCT) would be worth
$1,476.39
+$476.39 (+47.6%) today · 1.48× · US Dollar
Based on a PTCT entry price of $47.86 vs. today's $70.66.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $71.02 | $994.93 | -0.5% |
| 1 month ago | $69.22 | $1,020.8 | +2.1% |
| 3 months ago | $68.1 | $1,037.59 | +3.8% |
| 6 months ago | $85.99 | $821.72 | -17.8% |
| 1 year ago | $47.86 | $1,476.39 | +47.6% |
| All time (5.0y) ago | $38.86 | $1,818.32 | +81.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PTCT forecast.
Our base-case forecast reaches $140.00 around 2032.
Implied market cap at $140.00: $11.61B
The multi-year forecast paints a steady, bullish path with rising averages and meaningful upside as time extends. For 2026 the average price is projected at $68.81 with a range from $62.82 to $94.85 and a 0% ROI, reflecting neutral sentiment.
From 2027 onward, the average price climbs to $85.63 (2027), with a max of $112.50 and a projected ROI of 24.4%, followed by 2028 at $88.88 (max $120.50, ROI 29.2%) and 2029 at $99.34 (max $138.10, ROI 44.4%). By 2030 the average is $102.48 with a max of $145.53 and ROI of 48.9%, maintaining a bullish sentiment.
The forecast continues to lift through 2031–2035, with 2031 at $113.26, 2032 at $140.45, 2033 at $153.06, 2034 at $167.54, and 2035 at $183.33; corresponding max values rise to $163.89, $206.68, $228.72, $253.92, and $281.53, and ROI climbs to 64.6%, 104.1%, 122.4%, 143.5%, and 166.4% respectively, all with bullish sentiment.
Longer horizon projections show substantial upside, with 2040 averaging $278.66 (max $452.31, ROI 305) and 2050 averaging $496.40 (max $874.21, ROI 621.4), sustaining a bullish outlook. These figures are estimates and not guarantees, subject to market and company-specific risks.
Tap a question to reveal the answer.
Avg $102.48; min $77.49; max $145.53; ROI 48.9%; sentiment BULLISH.
The forecast shows bullish sentiment across the multi-year horizon, with rising averages (e.g., 2030 Avg $102.48; 2050 Avg $496.40) and higher potential upside (ROI up to 621.4%). These are estimates, not guarantees.
Yes. The 2035 max is $281.53, which exceeds $200.
Current price $68.81; Market cap $5.71B.
30-day range: low $58.83, high $80.48.
PTC Therapeutics, Inc. Community Discussion
0Share your PTC Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.